• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How First-Generic OMNIPAQUE Rivals At Amneal Pharmaceuticals (AMRX) Have Changed Its Investment Story

    Simply Wall St·07/18/2026 09:18:56
    Listen to the news
    • Amneal Pharmaceuticals recently received U.S. Food and Drug Administration approval for additional strengths and vial sizes of its iohexol radiographic contrast injection, including 350 mg iodine/mL in 50 mL, 75 mL, and 100 mL vials, and 300 mg iodine/mL in a 50 mL vial, expanding on its previously launched 300 mg iodine/mL 100 mL vial product.
    • These are the first generic versions referencing OMNIPAQUE across these presentations, positioning Amneal to cover most U.S. iohexol injection demand in a US$706 million market while offering hospitals and imaging centers more flexible supply options, subject to careful management of the product’s serious safety warnings.
    • We’ll now examine how becoming the first generic alternative to OMNIPAQUE across multiple iohexol presentations could influence Amneal’s broader investment narrative.

    AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Amneal Pharmaceuticals Investment Narrative Recap

    To own Amneal, you generally need to believe its mix of generics, complex injectables, and specialty drugs can support steady, profitable growth despite margin pressure and leverage. The new iohexol approvals expand Amneal’s reach in a US$706 million contrast market and may modestly reinforce its near term launch pipeline, but they do not change the core short term catalyst around executing on guidance and managing debt, or the key risk of ongoing pricing and regulatory pressure.

    The most relevant recent announcement is Amneal’s entry into complex inhalation with U.S. launches of albuterol and beclomethasone HFA aerosols in April 2026, which, like iohexol, adds another complex product stream to the portfolio. Together, these launches illustrate how Amneal is leaning on higher value generics and specialty-type products to support its 2026 revenue guidance of US$3.05 billion to US$3.15 billion while it works through sector wide pricing and compliance headwinds.

    Yet behind the appeal of first generic status in iohexol, investors should still be aware of the ongoing risk that...

    Read the full narrative on Amneal Pharmaceuticals (it's free!)

    Amneal Pharmaceuticals' narrative projects $3.6 billion revenue and $400.7 million earnings by 2029.

    Uncover how Amneal Pharmaceuticals' forecasts yield a $18.25 fair value, in line with its current price.

    Exploring Other Perspectives

    AMRX 1-Year Stock Price Chart
    AMRX 1-Year Stock Price Chart

    Some of the most optimistic analysts, who were already modeling about US$3.8 billion in revenue and US$409.4 million in earnings by 2029, see a far stronger biosimilars driven story than the consensus, and this iohexol news may eventually shift both that bullish view and the more cautious concerns about debt funded expansion in different directions.

    Explore 3 other fair value estimates on Amneal Pharmaceuticals - why the stock might be worth 33% less than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Seeking Other Investments?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.